High-dose busulfan and cyclophosphamide followed by autologous transplantation in patients with advanced breast cancer

Bone Marrow Transplantation

Volumn 17, Issue 5, 1996, Pages 769-774

  Demirer, T ^a,b   Buckner, C D ^a   Appelbaum, F R ^a   Clift, R ^a   Storb, R ^a   Myerson, D ^a   Lilleby, K ^a   Rowley, S ^a   Bensinger, W I ^a  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b Fred Hutchinson Cancer Research Center   (United States)

Author keywords

Breast cancer; Busulfan; Cyclophosphamide

Indexed keywords

BUSULFAN; CYCLOPHOSPHAMIDE;

ADULT; ADVANCED CANCER; ARTICLE; AUTOLOGOUS BONE MARROW TRANSPLANTATION; AUTOTRANSPLANTATION; BONE METASTASIS; BREAST CANCER; CANCER RECURRENCE; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG EFFICACY; DRUG SAFETY; HUMAN; LUNG ASPERGILLOSIS; METASTASIS; MORTALITY; PRIORITY JOURNAL; SIDE EFFECT; STEM CELL TRANSPLANTATION; SURVIVAL RATE; TREATMENT OUTCOME;

ADULT; ANTINEOPLASTIC AGENTS, ALKYLATING; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE MARROW TRANSPLANTATION; BREAST NEOPLASMS; BUSULFAN; COMBINED MODALITY THERAPY; CYCLOPHOSPHAMIDE; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MIDDLE AGED; RECURRENCE; TIME FACTORS; TRANSPLANTATION, AUTOLOGOUS;

EID: 0029884864     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Broder LE, Tormey DC. Combination chemotherapy of carcinoma of the breast. Cancer Treat Rev 1974; 1: 183-203.
2. Kolaric K, Roth A. Phase II clinical triai of cis-dichlorodiamine platinum (cis-DDP) for antitumorigenic activity in previously untreated patients with metastatic breast cancer. Cancer Chemother Pharmacol 1983; 11: 108-112.
3. Frei E, Canellos GP. A critical factor in cancer therapy. Am J Med 1980; 69: 585-594.
4. Herzig G. Autologous marrow transplantation in cancer therapy. Hematol 1981; 9: 1-24.
5. Kanfer EJ, Petersen FB, Buckner CD. Phase I study of high-dose dimethylbusulfan followed by autologous bone marrow transplantation in patients with advanced malignancy. Cancer Treat Rep 1987; 71: 101-102.
6. Buckner CD, Dillingham LA, Thomas ED et al. Toxologic and marrow transplantation studies in rhesus monkeys given dimethylmyeleran. Exp Hematol 1975; 3: 275-288.
7. Warwick GP. The mechanism action of alkylating agents. Cancer Res 1963; 23: 1315-1333.
8. Peters WP, Henner WD, Grochow LB et al. Clinical and pharmacologic effects of high dose single agent busulfan with autologous bone marrow support in the treatment of solid tumors. Cancer Res 1987; 47: 6402-6406.
9. Ghalie R, Reynolds J, Valentino LA et al. Busulfan-containing pre-transplant regimens for the treatment of solid tumors. Bone Marrow Transplant 1994; 14: 437-442.
10. Klumpp TR, Mangan KF, Glenn LD et al. Phase II pilot study of high-dose busulfan and CY followed by autologous BM or peripheral blood stem cell transplantation in patients with advanced chemosensitive breast cancer. Bone Marrow Transplant 1993; 11: 337-339.
11. Berenson RJ, Bensinger WI, Hill RS et al. Engraftment after infusion of CD34+ marrow cells in patients with breast cancer or neuroblastoma. Blood 1991; 77: 1717-1722.
12. Bensinger W, Appelbaum F, Buckner CD et al. Autologous transplantation with peripheral blood mononuclear cells collected after administration of recombinant granulocyte stimulating factor. Blood 1993; 11: 3158-3163.
13. Rowley SD, Bensinger WI. Buckner CD et al. Effect of cell concentration on bone marrow and peripheral blood stem cell cryopreservation. Blood 1994; 83: 2731-2736.
14. Bearman SI, Appelbaum FR, Buckner CD et al. Regimen related toxicity in patients undergoing bone marrow transplantation. J Clin Oncol 1988; 6: 1562-1568.
15. Clark JG, Hansen JA, Hertz MI et al. Idiopathic pneumonia syndrome following bone marrow transplantation. Am Rev Respir Dis 1993; 147: 1601-1606.
16. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457-481.
17. Frei E III, Cucchi CA, Roskowsky A et al. Alkylating agent resistance: in vitro studies with human cell lines. Proc Natl Acad Sci USA 1985; 28: 2158-2162.
18. Teicher B, Cucchi C, Lee J et al. Alkylating agents: in vitro studies of cross-resistance patterns in human tumor cell lines. Cancer Res 1986; 46: 4379-4383.
19. Teicher B, Holden S, Cucchi C et al. Combination of N,N′ N″-triethylenethiophosphoramide and cyclophosphamide in vitro and in vivo. Cancer Res 1988; 48: 94-100.
20. Eder P, Antman K, Peters WP et al. High-dose combination alkylating agent chemotherapy with autologous bone marrow support for metastatic breast cancer. J Clin Oncol 1986; 4: 1592-1597.
21. Peters WP, Shpall EJ, Jones RB et al. High-dose combination alkylating agents with bone marrow support as initial treatment for metastatic breast cancer. J Clin Oncol 1988; 6: 1368-1376.
22. Dunphy FR, Spitzer G, Buzdar A et al. Treatment of estrogen receptor negative or hormonally refractory breast cancer with double high-dose chemotherapy intensification and bone marrow support. J Clin Oncol 1990; 8: 1207-1216.
23. Antman K, Ayash L, Elias A et al. A phase II study of high-dose cyclophosphamide, thiotepa and carboplatin with autologous bone marrow support in women with measurable advanced breast cancer responding to standard-dose therapy. J Clin Oncol 1992; 10: 102-110.
24. Williams SF, Gilewski T, Mick R et al. High-dose consolidation therapy with autologous stem cell rescue in stage IV breast cancer: follow-up report. J Clin Oncol 1992; 10: 1743-1747.
25. Ayash LJ, Wheeler C, Reich E et al. Double dose-intensive chemotherapy with autologous marrow and peripheral blood progenitor-cell support for metastatic breast cancer: a feasibility study. J Clin Oncol 1994; 12: 37-44.
26. Vaughan WP, Reed EC, Kessinger A et al. High-dose cyclophosphamide, thiotepa and hydroxyurea with autologous hematopoietic stem cell rescue: an effective consolidation chemotherapy regimen for early metastatic breast cancer. Bone Marrow Transplant 1994; 13: 619-624.
27. Antman K, Gale RP. Advanced breast cancer: high-dose chemotherapy and bone marrow autotransplants. Ann Intern Med 1988; 108: 570-574.
28. Bensinger WI, Buckner CD, Clift RA et al. Phase I study of busulfan and cyclophosphamide in preparation for allogeneic marrow transplant for patients with multiple myeloma. J Clin Oncol 1992; 10: 1492-1497.
29. Shpall EJ, Jones RB, Bearman SI et al. Transplantation of enriched CD34-positive autologous marrow into breast cancer patients following high-dose chemotherapy: influence of CD34-positive peripheral blood progenitors and growth factors on engraftment. J Clin Oncol 1994; 12: 28-36.
30. Ross AA, Cooper BW, Lazarus HM et al. Detection and viability of tumor cells in peripheral blood stem cell collections from breast cancer patients using immunocytochemical and clonogenic assay techniques. Blood 1993; 82: 2605-2610.
31. Weaver CH, Bensinger WI, Buckner CD et al. Phase I study of high-dose busulfan, melphalan and thiotepa with autologous stem cell support in patients with refractory malignancies. Bone Marrow Transplant 1994; 14: 813-819.